Sulzer Medica reports strong first quarter:
This article was originally published in Clinica
Swiss company Sulzer Medica has seen sales rise 21% to SwFr 346 million ($235 million) in the first quarter. Adjusted for beneficial currency moves, the rise is 9%. The cardiovascular prosthesis division performed best, increasing 33% to SwFr 52 million, followed by pacemakers, up 22% to SwFr 112 million, and orthopaedics, up 17% to SwFr 184 million. In the summer, Sulzer Medica is planning to offer a quarter of its shares to the public in the US and Switzerland.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.